Exploration of the Active Component and Mechanisms of Shengyu Decoction Against Myelosuppression Using Network Pharmacology and in vitro Experimental Validation
DOI: https://doi.org/10.2147/dddt.s458953
IF: 4.3188
2024-06-20
Drug Design Development and Therapy
Abstract:Bingjie Ma, 1 Pengyi Hou, 2 Ran Liu, 3 Aijun Cang, 1 Limei Zhao 4 1 Department of Pharmacy, People's Hospital of Liaoning Province, Shenyang, 110010, People's Republic of China; 2 SCIEX Analytical Instrument Trading Co, Shanghai, 200000, People's Republic of China; 3 School of Food and Drug, Shenzhen Polytechnic, Shenzhen, 518000, People's Republic of China; 4 Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, 110010, People's Republic of China Correspondence: Limei Zhao, Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, 110010, People's Republic of China, Email Background: Chemotherapy-induced myelosuppression (CIM) is a common adverse reaction with a high incidence rate that seriously affects human health. Shengyu Decoction (SYD) is often used to treat CIM. However, its pharmacodynamic basis and therapeutic mechanisms remain unclear. Purpose: This study aimed to clarify the active components and mechanisms of SYD in CIM. Methods: LC-QTOF/MS was used to identify the absorbable components of SYD. A series of network pharmacology methods have been applied to explore hub targets and potential mechanisms. Molecular docking was used to identify the binding ability of potential active ingredients and hub targets. Finally, in vitro experiments were performed to validate these findings. Results: In this study, 33 absorbable prototype components were identified using LC-QTOF/MS. A total of 62 possible targets of SYD in myelosuppression were identified. KEGG pathway enrichment analyses showed that some signaling pathways such as PI3K-Akt and HIF-1 may be the mechanisms by which it functions. Among them, we verified the PI3K-Akt pathway. 6 Hub proteins were screened by Protein–protein interaction (PPI) network analysis. Molecular docking results showed that four absorbable components in SYD showed good binding with six Hub targets. The effectiveness of the four predicted compounds and the mechanism were verified in vitro. It has also been shown that the active component could promote the proliferation of bone marrow stromal cells (BMSCs) and block apoptosis of BMSCs, which may be related to the PI3K-Akt pathway. This result is consistent with the network pharmacology approach and molecular docking predictions. Conclusion: Our results provided not only the candidate active component of SYD, but also a new insights into mechanism of SYD in the treatment of CIM. Keywords: Shengyu decoction, SYD, myelosuppression, network pharmacology, molecular docking, active components, mechanism Graphical Cancer is a broad group of diseases that involve unregulated cell growth and is internationally acknowledged as one of the main causes of human death and heavily imperiling human life. 1,2 Chemotherapeutic drugs are crucial tools in malignancy treatment and are frequently accompanied by serious side effects. 3,4 Myelosuppression is one of the serious side effects, which may even cause serious mortality problems, making alleviating Chemotherapy-induced myelosuppression (CIM) an important issue in clinical cancer treatments. 5 Currently, the treatment of CIM is mainly symptomatic, including biological agents (colony-stimulating factor, et al) and blood products. However, these drugs may lead to vascular events and lung injury, and even promote cancer development and metastasis. 6 Therefore, the development of a safe and effective drug to treat CIM is imperative. The long-term clinical use of Traditional Chinese medicine (TCM) has led to the accumulation of valuable experience in the treatment of CIM. 7–9 Shengyu Decoction (SYD) is a classical prescription in ancient China, which was first mentioned in Mai Yin Zheng Zhi, a famous medical monograph of the Yuan Dynasty. SYD is believed to treat myelosuppression by replenishing qi and the blood. SYD is composed of six herbs: Radix Rehmanniae Praeparata (shudihuang, SDH), Ginseng (renshen, RS), Radix Paeoniae Alba (baishao, BS), Rhizoma Chuanxiong (Chuanxiong, CX), Radix Angelicae Sinensis (danggui, DG), and Radix Astragali (huangqi, HQ). Studies have revealed that iridoid and phenylpropanoid glycosides are characteristic components of SDH; BS is abundant in monoterpenes; DG and CX are rich in organic acids and essential oils; RS is distinguished by the presence of ginsenosides; And HQ is distinguished by the presence of flavonoids. These extracts and compounds have a broad range of pharmacological activities, such as hemopoietic, immunoregulatory, anti-inflammatory, antibacterial, antiviral, antioxidant, and antitumor activities. 10–13 However, the prima -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal